Cell-Based Vaccine Production Would Open Market To Small Suppliers – AEI's Gottlieb
This article was originally published in The Pink Sheet Daily
Executive Summary
Cell-based manufacturing would allow smaller manufacturers to enter the flu vaccine market, American Enterprise Institute fellow Scott Gottlieb, MD, said Dec. 7
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.
Baxter Suspends PreFluCel Studies Until Phase II/III Data Are Analyzed
Due to a higher than expected rate of mild fever and associated symptoms in a European trial, Baxter places PreFluCel clinical trials planned for 2005 on hold. PreFluCel is based on Baxter's vero cell technology platform.